Adjuvant Pembrolizumab Approval Adds to Prevention of Recurrent NSCLC
February 2nd 2023An expert from Yale School of Medicine discusses how the approval of adjuvant pembrolizumab expands treatment to include patients with IB, II, III, and IIIA resected, early-stage, non–small cell lung cancer regardless of PD-L1 expression.
Roy S. Herbst, MD, PhD, Reviews Ramucirumab Plus Pembrolizumab in ICI-Resistant NSCLC
August 3rd 2022At 2022 ASCO, Roy S. Herbst, MD, PhD, spoke about the results of a Lung-MAP substudy showing benefit of ramucirumab plus pembrolizumab vs standard of care chemotherapy for patients with advanced non–small cell lung cancer who demonstrated resistance to prior immunotherapy.
Expert on Emergence of Osimertinib, New Discoveries in Lung Cancer Care
June 15th 2020Roy S. Herbst, MD, PhD, presented a late breaking abstract on behalf of his colleagues regarding the ADAURA trial, which analyzed osimertinib as an adjuvant therapy to treat patients with non-small cell lung cancer.
Roy S. Herbst, MD, PhD, Discusses ADAURA Trial and Future of Lung Cancer Treatment
June 12th 2020Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed the future of lung cancer treatment to follow the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.
Roy S. Herbst, MD, PhD, Talks Key Takeaway from Phase III ADAURA Trial
June 3rd 2020Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.